Horizon 2020 (2014 - 2020)

Linking Clinical Neuropsychiatry and Quantitative Neurobiology

Last update: Aug 18, 2020 Last update: Aug 18, 2020

Details

Location:EU 27
EU 27
Contracting authority type:Development Institution
Status:Awarded
Budget: EUR 16,160,000
Award ceiling:N/A
Award floor:N/A
Sector:Health, Research
Eligible applicants:Unrestricted / Unspecified
Eligible citizenships:EU 27, Albania, Armenia, Bosnia ...
See more
EU 27, Albania, Armenia, Bosnia and Herzegovina, Georgia, Iceland, Israel, Moldova, Montenegro, North Macedonia, Norway, Serbia, Switzerland, Tunisia, Turkey, Ukraine
Date posted: Dec 18, 2014

Attachments 1

Description

Call updates:
09 March 2015 14:57

Deadline for submission approaching: 24 March 2015 17:00 Brussels time

Webinar presentations for all topics now available.

15 January 2015 17:56 The submission session is now available for: IMI2-2015-03-03(IMI2-RIA-IA)

TOPIC : Linking Clinical Neuropsychiatry and Quantitative Neurobiology

Topic identifier: IMI2-2015-03-03
Publication date: 17 December 2014

Types of action: IMI2-RIA Research and Innovation action
DeadlineModel:
Opening date:
two-stage
17 December 2014
Deadline:
2nd stage Deadline:
24 March 2015 17:00:00
29 September 2015 17:00:00

Time Zone : (Brussels time)
 
  Horizon 2020
Call identifier: H2020-JTI-IMI2-2015-03-TWO-STAGE
Topic Description
Scope:

Specific Challenge

The challenge is to initiate the process to move towards a quantitative biology based framework for neuropsychiatry disorders. This is needed both to reverse the stagnation in treatment development of classical psychiatric disorders, and to address the need to treat neuropsychiatric issues associated with the increasing burden of neurodegenerative disease.

Scope

The overall scope will be to explore the same set of quantifiable biological parameters across selected symptom constellations common to distinctly classified syndromes by classical taxonomy.

These studies would be driven from clinical quantitative biology back through appropriate translation to the measurement of homologous pre-clinical quantitative biological indices.

Expected Impact

New classification of the disease for stratification of patients to facilitate more effective treatment and design of clinical trials, including the standardisation of measurement across sites. Identification of best predictive systems- clinical, non-clinical and pre-clinical – to explore the underlying biological process for identification and development of novel therapies or targets

Budget IMI contribution: EUR 8 080 000

EFPIA contribution: EUR 8 080 000

Total: EUR 16 160 000

Want to unlock full information?
Member-only information. Become a member to access this information. Procurement notices from over 112+ donors and banks are available here